Bristol-Myers Squibb Co.(BMY: Quote) announced today that the Company has suspended study drug administration in an ongoing Phase II study of BMS-986094 (formerly known as INX-189), a nucleotide polymerase or NS5B inhibitor in development for the treatment of hepatitis C.
This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue. The cause of the safety issue and any potential relationship to study drug are unknown at this time, the company said.
The company noted that it is undertaking an immediate assessment of all patients in the study and following an evaluation of the patient data, will take appropriate actions.
Click here to receive FREE breaking news email alerts for Bristol-Myers Squibb Co. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com